Omaveloxolone (RTA-408) - 98%, high purity , CAS No.1474034-05-3, Activator of nuclear factor; erythroid 2 like 2

Item Number
O413808
Grouped product items
SKUSizeAvailabilityPrice Qty
O413808-2mg
2mg
In stock
$51.90
O413808-5mg
5mg
In stock
$107.90
O413808-10mg
10mg
In stock
$147.90
O413808-25mg
25mg
In stock
$333.90
O413808-50mg
50mg
In stock
$444.90
O413808-100mg
100mg
In stock
$642.90

Nrf2 Activators

Basic Description

SynonymsDTXSID101138251 | GTPL7573 | MFCD28167769 | N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoropropanamide | omaveloxolona | AKOS037648676 | N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsOmaveloxolone (RTA-408) is a synthetic triterpenoid that activates the cytoprotective transcription factor Nrf2 and inhibits NF-κB signaling. Phase 2.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeACTIVATOR
Mechanism of actionActivator of nuclear factor; erythroid 2 like 2
Product Description

Information

Omaveloxolone (RTA-408) Omaveloxolone (RTA-408) is a synthetic triterpenoid that activates the cytoprotective transcription factor Nrf2 and inhibits NF-κB signaling. Phase 2.


Targets

NF-κB ; Nrf2


In vitro

RTA 408 potently increases expression of Nrf2 target genes and reverses IFNγ-mediated suppression of Gclc expression in RAW 264.7 cells. In a panel of eight human tumor cell lines, RTA 408 inhibits growth with an average GI50 value of 260 nM and induces apoptosis. RTA 408 also inhibits NF-κB and activates JNK in tumor cells.


In vivo

In mice with radiation-induced dermatitis, 1.0% RTA 408 markedly reduces epidermal and collagen thickening, prevents dermal necrosis and completely alleviates skin ulcers. In rat skin, RTA 408 activates Nrf2 and induces cytoprotective genes. RTA 408 also mitigates hematopoietic acute radiation syndrome in mice.


Cell Research(from reference)

Cell lines:A375, NCI-H460, A2058, MDA-Mb-231, HCT116, 786-0, A549, and PANC-1 cells 

Concentrations:~1 μM 

Incubation Time:72 hours 

Product Properties

ALogP5.339
HBD Count1
Rotatable Bond2

Associated Targets(Human)

NFE2L2 Tchem Nuclear factor erythroid 2-related factor 2 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
HT-29 (80576 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

L929 (3802 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

Pubchem Sid488202305
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488202305
IUPAC Name N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide
INCHI InChI=1S/C33H44F2N2O3/c1-27(2)11-13-33(37-26(40)32(8,34)35)14-12-31(7)24(20(33)17-27)21(38)15-23-29(5)16-19(18-36)25(39)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3,(H,37,40)/t20-,22-,24-,29-,30+,31+,33-/m0/s1
InChi Key RJCWBNBKOKFWNY-IDPLTSGASA-N
Canonical SMILES CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)NC(=O)C(C)(F)F)C
Isomeric SMILES C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)NC(=O)C(C)(F)F
Alternate CAS 1474034-05-3
PubChem CID 71811910
MeSH Entry Terms N-(11-cyano-2,2,6a,6b,9,9,12a-heptmethyl-10,14-dioxo-1,3,4,5,6a,6b,7,8,8a,9,10,12a,14,14a,14b-hexadecahydro-2H-picen-4a-yl)-2-2-difluoropropionamide;Omaveloxolone;RTA 408;RTA-408
Molecular Weight 554.71

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

12 results found

Lot NumberCertificate TypeDateItem
B2327605Certificate of AnalysisAug 25, 2022 O413808
B2327608Certificate of AnalysisAug 25, 2022 O413808
B2327612Certificate of AnalysisAug 25, 2022 O413808
B2327613Certificate of AnalysisAug 25, 2022 O413808
B2327617Certificate of AnalysisAug 25, 2022 O413808
B2327642Certificate of AnalysisAug 25, 2022 O413808
B2327644Certificate of AnalysisAug 25, 2022 O413808
B2327645Certificate of AnalysisAug 25, 2022 O413808
B2327646Certificate of AnalysisAug 25, 2022 O413808
B2327647Certificate of AnalysisAug 25, 2022 O413808
B2327648Certificate of AnalysisAug 25, 2022 O413808
B2327669Certificate of AnalysisAug 25, 2022 O413808

Show more⌵

Chemical and Physical Properties

SolubilitySolubility (25°C) In vitro DMSO: 100 mg/mL (180.27 mM); Ethanol: 3 mg/mL (5.4 mM); Water: Insoluble;
DMSO(mg / mL) Max Solubility100
DMSO(mM) Max Solubility180.2743776
Water(mg / mL) Max Solubility<1

Related Documents

References

1. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Ward KW.  (2014)  Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin..  Arch Dermatol Res,  306  (5): (447-54).  [PMID:24362512] [10.1021/op500134e]
2. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Sonis ST, Ward KW.  (2014)  Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis..  Radiat Res,  181  (5): (512-20).  [PMID:24720753] [10.1021/op500134e]
3. Reisman SA, Gahir SS, Lee CI, Proksch JW, Sakamoto M, Ward KW.  (2019)  Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates..  Drug Des Devel Ther,  13  (13): (1259-1270).  [PMID:31118567] [10.1021/op500134e]
4. Ghanekar SD, Miller WW, Meyer CJ, Fenelon KJ, Lacdao A, Zesiewicz TA.  (2019)  Orphan Drugs In Development For The Treatment Of Friedreich's Ataxia: Focus On Omaveloxolone..  Degener Neurol Neuromuscul Dis,  (13): (103-107).  [PMID:31686946] [10.1021/op500134e]
5. Profeta V, McIntyre K, Wells M, Park C, Lynch DR.  (2023)  Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia..  Expert Opin Investig Drugs,  32  (1): (5-16).  [PMID:36708320] [10.1021/op500134e]

Solution Calculators